During treatments of immune checkpoint inhibitors such as antibodies against PD-1 or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), tumor responses were observed and assessed using Response Evaluation Criteria in Solid Tumors (RECIST) [2]. The gene discussed is CTLA4; the disease is neoplasm.